BioNxt获得欧盟的无针阴唇治疗专利,在2043年之前在39个国家保护这一专利。 BioNxt gains EU patent for needle-free cladribine treatment, protecting it in 39 countries until 2043.

BioNxt Solutions Inc.已收到欧洲专利局关于批准一项专利的决定,该专利涵盖其用于Cladribine的亚语言口服薄膜交付系统的低语言口服薄膜,这是发展多发性硬化症的一种治疗方法。 BioNxt Solutions Inc. has received a Decision to Grant from the European Patent Office for a patent covering its sublingual oral thin film delivery system for cladribine, a treatment in development for multiple sclerosis. 该专利自2026年3月11日起生效, 将至少通过2043年6月14日保护39个欧洲国家的技术。 The patent, effective March 11, 2026, will protect the technology in up to 39 European countries through at least June 14, 2043. 无针、无燕子的配方旨在改善患者,特别是有吞咽困难的患者遵守规定的情况。 The needle-free, swallow-free formulation aims to improve patient adherence, especially for those with swallowing difficulties. 专利还涵盖其他自体免疫和神经退化条件下的潜在用途。 The patent also covers potential uses in other autoimmune and neurodegenerative conditions. 这个里程碑支持BioNxt的领先候选者BNT23001,推动人类生物等效研究,并加强其全球知识产权战略,包括美国和加拿大的专利努力。 This milestone supports BioNxt’s lead candidate, BNT23001, advancing toward human bioequivalence studies, and strengthens its global intellectual property strategy, including U.S. and Canadian patent efforts.